Melanotan II: The Complete Guide
The tanning peptide with the largest gap between how casually it is discussed and what the dermatology literature actually documents. Here is the full picture, including the parts that get left out.
This guide covers the pharmacology, published human research, documented adverse events and regulatory history of Melanotan II. It is educational only and not a substitute for advice from a qualified healthcare professional. Sources are listed at the end.
Read this before the rest of the page
Melanotan II stimulates melanocytes — the same cells melanoma arises from. The published dermatology literature contains multiple case reports of new moles erupting within days of use, existing moles darkening and changing shape, dysplastic nevi with severe atypia, and melanoma diagnosed in users within weeks to months of a course. Causation has not been established, and some of these people also used tanning beds. But there is a second problem that does not depend on causation at all: MT-II darkens every mole you have, which makes the visual changes dermatologists rely on to catch melanoma early far harder to read. Anyone considering this compound should have a baseline full-skin examination by a dermatologist first, and anyone already using it who notices a mole change colour, shape or size should stop and get it looked at without waiting. This applies with particular force if you have fair skin, many moles, a personal or family history of melanoma, or a lot of sun exposure — which describes most of the people this compound is marketed to.
Melanotan II occupies an unusual position. It is one of the most widely used compounds in the grey peptide market, it has a nickname in the tabloid press, and it has never been approved by any regulator anywhere in the world for any purpose. Its close chemical relatives, meanwhile, have both been approved — one for a rare light-sensitivity disorder, one for low sexual desire.
That contrast is the most useful thing to understand about it, and it runs through everything below.
What Melanotan II Is
MT-II is a synthetic analogue of alpha-melanocyte-stimulating hormone (α-MSH), the hormone that tells pigment cells to make melanin. Structurally it is a cyclic lactam — a ring rather than a straight chain — built around seven residues, which makes it far more resistant to breakdown than the natural hormone and considerably more potent.
It came out of the University of Arizona in the 1980s, from the same group that developed the compound now known as afamelanotide. The original scientific goal was interesting and defensible: if you could induce melanin production without ultraviolet exposure, you might give people the photoprotection of a tan without the DNA damage of getting one. That premise still has scientific merit. What happened to MT-II afterwards is a different story.
The compound never completed the trials that would have tested the premise. It leaked into the fitness and tanning-salon market instead, where it has been sold ever since as an unregulated injectable.
MT-I vs MT-II vs PT-141
Three closely related compounds get conflated constantly, and the differences between them are the difference between an approved medicine and an unapproved one.
| Compound | Receptor targets | Status | What that means |
|---|---|---|---|
| Afamelanotide (Melanotan I) | Selective for MC1R — the pigment receptor | Approved by the EMA in 2014 and the FDA in 2019, for erythropoietic protoporphyria | Went through full trials for a specific rare disease. Delivered as an implant under specialist supervision |
| Melanotan II | Non-selective — hits MC1R, MC3R, MC4R and MC5R | Never approved anywhere, for anything | The receptor promiscuity is why it also affects appetite and erections. Those are not bonus features; they are off-target effects |
| Bremelanotide (PT-141) | Primarily MC4R | FDA approved in 2019 for hypoactive sexual desire disorder in premenopausal women | Derived from MT-II — it is an active metabolite. Went through the trials MT-II never did |
The pattern worth noticing
Both compounds that were narrowed to a single receptor and taken through proper trials got approved. The one that hits everything at once and skipped the trials did not. If sexual function rather than tanning is the actual interest, PT-141 is the compound with human trial data and an approval behind it — see also our page on peptides for libido and sexual health.
Simplified. Receptor affinities vary and MT-II's relative potency differs across the four subtypes.
How It Works
Binding MC1R on melanocytes triggers the production of eumelanin, the darker of the two melanin types, and the skin darkens without needing ultraviolet light to initiate it. This is real pharmacology and it works — the tanning effect is not in dispute.
Two things are worth understanding about that mechanism. First, MC1R activation stimulates not just pigment production but melanocyte proliferation — the cells themselves multiply. Second, MC1R sits on every melanocyte in the body, including the ones inside existing moles. The compound cannot distinguish between an ordinary melanocyte and one in a lesion that already carries mutations.
MC1R — pigmentation
The intended target. Drives eumelanin synthesis and melanocyte proliferation. Also the reason moles darken.
MC4R — appetite and arousal
Produces the appetite suppression and spontaneous erections reported by users. This is the receptor bremelanotide was developed around.
MC3R — energy balance
Contributes to metabolic and inflammatory effects. Less well characterised in humans than the other two.
MC5R — sebaceous glands
Implicated in the increased oiliness and acne some users report.
What the Human Research Shows
Here is the part that surprises people who have seen how confidently MT-II is discussed online: the human trial base is tiny.
The most cited human study is a small 1998 trial published in the Journal of Urology examining erectile response — not tanning. Beyond a handful of small early-phase pilot studies from the 1990s and 2000s, there is no completed phase 3 programme, no large randomised trial of MT-II for tanning, and no long-term safety follow-up of any kind.
What exists instead is a substantial dermatology case-report literature, and it is not describing benefits. A 2017 systematic review in the International Journal of Dermatology gathered the published cutaneous complications of unregulated melanotan use. The picture that emerges from three decades of unregulated availability is one where the documented human evidence is overwhelmingly about harm, because nobody ever ran the trials that would have documented anything else.
The Melanoma Question
This section carries the weight of the page, so it is worth being precise about what is and is not established.
What has been reported
- Eruptive nevi. New moles appearing in crops — in one published case, within 24 hours of a single subcutaneous injection in a 24-year-old man.
- Darkening and change of existing moles. Reported consistently across the case literature, including changes in colour, size and growth characteristics.
- Dysplastic nevi. A 25-year-old man developed multiple new nevi and rapid transformation of existing ones weeks after a four-week course, with histology showing severe dysplasia.
- Melanoma. Several published cases, including a 20-year-old woman with fair skin diagnosed with melanoma on the buttock three months after a three-to-four-week MT-II course combined with sunbed use, and a 42-year-old woman whose previously stable mole changed over three months following MT-II injections.
- Mucosal and nail pigmentation. Darkening of oral mucosa and longitudinal nail pigmentation have both been documented.
The most informative case in the literature
Nevi that changed, then changed back
A 40-year-old man with a personal history of melanoma and multiple dysplastic nevi self-administered synthetic α-MSH. He developed crops of new pigmented nevi, many clinically and histologically atypical, while his existing nevi darkened and acquired growth features. After he stopped, the nevi progressively lightened and lost those growth features. The authors concluded that synthetic α-MSH peptides can drive proliferation of neoplastic melanocytic cells in predisposed people. A reversible, dose-related effect appearing on exposure and receding on withdrawal is about as close to a causal signal as observational human data gets.
What is not established
No controlled study has shown that MT-II causes melanoma, and it would be dishonest to claim otherwise. Confounding is genuine: people who inject a tanning peptide are, as a group, also people who seek sun and use tanning beds, which is itself the dominant melanoma risk factor. Some researchers have argued the observed melanoma cases may reflect that behaviour rather than the drug.
That argument has a limit, though. It explains why the melanoma cases might not be caused by MT-II. It does not explain away the eruptive nevi and mole darkening, which appear within days, in patterns not attributable to sun exposure, and which reverse on withdrawal.
The surveillance problem nobody mentions
Set causation aside entirely and a separate risk remains. Early melanoma detection depends almost entirely on noticing change — a mole that is darker, larger, or differently shaped than it was. MT-II darkens every mole on your body simultaneously and can generate dozens of new ones. Dermatologists reviewing users have described the resulting difficulty distinguishing a nevus from a melanoma on dermoscopy.
In other words, the compound degrades the exact signal that early detection relies on, at the same time as it stimulates the cell type in question. Even on the most charitable reading of the causation evidence, that combination is a poor trade.
Situations where the risk is highest
Fair skin, red or blond hair, many freckles. These are precisely the people the tan appeals to and precisely the people with the most melanoma risk to begin with. A high mole count, or any atypical moles. More than five dysplastic nevi is an independent melanoma risk factor. Personal or family history of melanoma, and especially familial atypical mole–melanoma syndrome — published cases in this group are among the most alarming in the literature. Combining with tanning beds or heavy sun exposure. Most published melanoma cases involved exactly this combination, and it is what MT-II is typically used to accelerate. In Costa Rica, where the UV index runs high year-round and outdoor life is the norm, baseline exposure is already substantial before anything is added to it.
Other Documented Harms
The melanocytic effects dominate the discussion, but the case literature includes other events worth knowing about.
| Effect | What is documented |
|---|---|
| Nausea and flushing | The most common reported effects, typically worst in the first weeks and at higher doses. Often accompanied by facial flushing shortly after injection |
| Spontaneous erections and priapism | An MC4R effect. Priapism — a sustained, painful erection — is a urological emergency and has been reported at higher doses |
| Rhabdomyolysis | Breakdown of muscle tissue that can damage the kidneys. Reported in the case literature, associated with higher-dose use |
| Posterior reversible encephalopathy syndrome | A neurological syndrome involving headache, seizures and visual disturbance, reported in at least one case linked to melanotan use |
| Blood pressure effects | Melanocortin receptors are involved in cardiovascular regulation; both blood pressure and heart rate changes have been described |
| Appetite suppression | Reliable enough that some users treat it as a feature. It is an MC4R off-target effect with no dosing control |
General guidance on reducing the more mundane effects is in our page on how to minimize peptide side effects — though it is worth saying plainly that better injection technique does nothing about the melanocytic risks above.
Dosing in the Research
No dose of MT-II has ever been validated for tanning in a human trial, and no regulator has ever set one. The figures below are provenance, not guidance.
| Source | Dose reported | Notes |
|---|---|---|
| Early clinical studies | Approximately 0.025–0.03 mg/kg | Small pilot studies, mostly examining erectile response rather than tanning |
| Community loading protocols | Around 0.25–0.5 mg daily | Not derived from any trial. The loading-then-maintenance structure is convention |
| Community maintenance | One to two doses weekly | Continued indefinitely by some users, with no long-term safety data of any kind |
| Overdose case reports | Higher than the above | Associated with the severe events in the previous section, including rhabdomyolysis and priapism |
One structural point: because a tan is visible and cumulative, users have an obvious incentive to push the dose to get there faster. That is the opposite of how the risk profile is shaped, since the severe events cluster at higher doses.
The Product Quality Problem
MT-II has never been manufactured under pharmaceutical standards for human use anywhere, because no regulator has ever authorised it. Everything in circulation comes from the research-chemical supply chain.
A 2022 observational study in the Journal of the American Academy of Dermatology examined 35 online distributors selling α-MSH analogues and documented inconsistent labelling, variable purity claims, and marketing language that overstated benefits while understating risks. About two-thirds of them labelled the product research-use-only while marketing it in ways that clearly anticipated human use.
Practically, this means you are combining an unvalidated dose of an unapproved compound with uncertain identity and purity. Our guides on understanding peptide purity and COAs and research versus pharmaceutical peptides explain what the documentation can and cannot tell you, and our COA database holds the results for what we carry.
Regulatory Status
MT-II has one of the longest enforcement histories of any compound in this catalogue.
- 2007 — the FDA issued a warning letter to a US distributor marketing MT-II as an injectable tanning product, stating it was an unapproved new drug.
- 2009 — the UK's MHRA issued a public warning, classifying melanotan as an unlicensed medicine whose safety had not been established. Australia's TGA has taken parallel action.
- 2015–2016 — the same US case resulted in a criminal plea and permanent debarment.
- 2023 — the FDA placed MT-II in Category 2 of the 503A bulk drug substances list, the designation for substances with identified significant safety risks.
- April 2026 — MT-II was among twelve substances removed from Category 2 for further evaluation. Removal is not approval and does not make compounding lawful.
- By end of February 2027 — the Pharmacy Compounding Advisory Committee is scheduled to review MT-II alongside GHK-Cu, LL-37, dihexa acetate and PEG-MGF. It was placed in this later group rather than the July 2026 tranche.
Two things to hold onto. A favourable committee vote would still be advisory and non-binding, would require separate rulemaking, and would not make MT-II an approved medicine. And MT-II remains not approved as a finished pharmaceutical drug by the FDA, the EMA, or Costa Rica's Ministerio de Salud — a status unchanged since the 1980s.
Common Questions
Does Melanotan II actually work for tanning?
Yes — the pigmentation effect is real and well understood mechanistically. That is precisely why the risk discussion matters. If it did nothing, there would be nothing to weigh.
Does it protect against sunburn or skin cancer?
That was the original scientific hypothesis, and it was never demonstrated for MT-II in trials. Do not treat a MT-II tan as sun protection. A tan of any origin provides only marginal protection, and the case literature points the opposite direction on skin cancer risk rather than the reassuring one.
Is it safer if I avoid sunbeds?
It removes the biggest confounder and one of the largest independent risk factors, so it is better. It does not address the melanocytic effects themselves — the eruptive nevi cases were not attributable to UV exposure. And people generally use MT-II to tan more, not less.
Do the mole changes reverse if I stop?
In the published cases, darkened nevi lightened and lost growth features after discontinuation. That is genuinely reassuring as far as it goes. It says nothing about whether a proliferation event during exposure left something behind, which is the concern that cannot be resolved by watching pigment fade.
What does the nasal spray version change?
The route, and not much else. Nasal formulations have circulated for years and avoid the injection, but they deliver the same compound to the same receptors with the same systemic effects and even less dose control. Nothing about the melanocytic concerns is route-specific.
Why is PT-141 legal and MT-II isn't, if one comes from the other?
Because a company took bremelanotide through the full trial programme for a defined indication and the FDA approved it in 2019. MT-II never went through that process. Regulatory status tracks whether someone did the work, not whether a molecule is chemically respectable.
Are athletes affected?
MT-II has no approval by any governmental health authority for human therapeutic use, which places it within WADA's S0 category — prohibited at all times, in and out of competition. Confirm with your national anti-doping organisation.
How should it be stored?
Lyophilized vials keep refrigerated and protected from light; reconstituted solution stays refrigerated and is used within a short window. Our guides on reconstitution and storing peptides in tropical climates cover the practical side.
What does Peptides Costa Rica carry, and what does it cost?
Current vial sizes, pricing and stock are on the MT-II product page, and five or more vials of the same product carry an automatic 15% discount. We would rather you read this page first — and if what you actually want is the sexual-function effect rather than the tan, say so and we will point you at the compound with trial data behind it instead.
Is it legal in Costa Rica?
It is sold here as a research compound and is not approved as a finished pharmaceutical drug by the Ministerio de Salud, the FDA or the EMA. Several countries have taken active enforcement action against vendors selling it for human use. Our FAQ page covers ordering locally.
Questions about Melanotan II?
We would rather talk you through the risk picture honestly than sell you something you would regret. If your goal is achievable another way, we will tell you — including when the answer is "see a dermatologist first."
Contact Us on WhatsAppImportant disclaimer: The information in this guide is general educational content only. It is not medical advice, a prescription, or a personalized recommendation. Melanotan II has never been approved by the FDA, the EMA, Costa Rica's Ministerio de Salud, or any other regulatory authority for any indication, and is sold as a research compound intended for laboratory and scientific study. It is not a treatment for anything, is not a sunscreen, and should not be relied upon for protection against ultraviolet damage or skin cancer. In April 2026 the FDA removed Melanotan II from Category 2 of the 503A bulk drug substances list pending review by the Pharmacy Compounding Advisory Committee scheduled before the end of February 2027; that removal is not approval, does not authorise compounding, and does not change the compound's legal status. Melanotan II is distinct from afamelanotide and from bremelanotide, both of which hold regulatory approvals it does not. The human efficacy evidence consists of small early-phase studies; no completed phase 3 trial and no long-term safety data exist. Dosing figures discussed reflect what appears in published studies and community use; they are not endorsements of those doses for any individual, and no dose has been validated for tanning in a human trial. The published dermatology literature documents eruptive melanocytic nevi, darkening and change of existing nevi, dysplastic nevi, and cases of melanoma in users; a causal relationship has not been established in controlled studies, and confounding by ultraviolet exposure is plausible. Additional documented adverse events include nausea, flushing, priapism, rhabdomyolysis, posterior reversible encephalopathy syndrome and blood pressure changes. Melanotan II darkens existing moles and may impair the visual surveillance used for early melanoma detection. Anyone considering or using this compound should have a baseline dermatological examination and ongoing skin monitoring, and any changing pigmented lesion requires prompt medical assessment. No safety data exists for pregnancy, breastfeeding or long-term use. Melanotan II falls within WADA's S0 non-approved substances category and should be treated as prohibited in tested sport. Always consult a qualified healthcare professional before beginning any peptide protocol. Products sold by Peptides Costa Rica are intended for laboratory and research purposes only.
- International Journal of Dermatology (Habbema et al., 2017): Systematic review of cutaneous complications associated with unregulated melanotan I and II use, and discussion of afamelanotide as the only approved α-MSH analogue.
- Dermatology, Karger (Hjuler & Lorentzen, 2014): Melanoma associated with Melanotan II use — a 20-year-old woman with Fitzpatrick type II skin diagnosed three months after a three-to-four-week course combined with sunbed use.
- British Journal of Dermatology (2011): Melanotan-associated melanoma in a 42-year-old woman, with change in a previously stable naevus over three months following subcutaneous injection.
- Archives of Dermatology (Cardones & Grichnik): A 40-year-old man with prior melanoma developed crops of atypical nevi and darkening of existing nevi during synthetic α-MSH use, which regressed after discontinuation; authors concluded α-MSH analogues can drive proliferation of neoplastic melanocytes in predisposed individuals.
- Actas Dermo-Sifiliográficas and British Journal of Dermatology case reports: Eruptive dysplastic nevi following a four-week Melanotan II course, and eruptive nevi with darkening of pre-existing nevi within 24 hours of a single injection.
- Journal of the American Academy of Dermatology (Hadeler et al., 2022): Observational study of 35 online distributors of α-MSH analogues documenting inconsistent labelling, purity claims and marketing language.
- Journal of Urology (Wessells et al., 1998): Small early human study of Melanotan II examining erectile response — the most cited controlled human data on the compound.
- U.S. Food and Drug Administration: Warning letter and subsequent Notice of Opportunity for Hearing regarding marketing of Melanotan II as an unapproved new drug, and 503A bulk drug substances categorisation.
- UK Medicines and Healthcare products Regulatory Agency (2009) and Australian Therapeutic Goods Administration: Public warnings classifying melanotan products as unlicensed medicines of unestablished safety.
- FDA regulatory tracking and legal analysis (2026): Removal of twelve substances from 503A Category 2 in April 2026 and the scheduling of Melanotan II for Pharmacy Compounding Advisory Committee review before the end of February 2027.
